Comparative Pharmacology
Head-to-head clinical analysis: INVAGESIC versus PROPOXYPHENE COMPOUND 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVAGESIC versus PROPOXYPHENE COMPOUND 65.
INVAGESIC vs PROPOXYPHENE COMPOUND 65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
Propoxyphene is an opioid analgesic that binds to mu-opioid receptors in the central nervous system, resulting in inhibition of ascending pain pathways and alteration of pain perception. Acetaminophen component inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
Adults: 1 capsule (65 mg propoxyphene HCl + 650 mg acetaminophen) orally every 4 hours as needed; maximum 6 capsules per day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
The terminal elimination half-life of propoxyphene is approximately 8-24 hours (mean 12 hours) in healthy adults. The half-life of its active metabolite, norpropoxyphene, is 30-36 hours, leading to prolonged effects and potential accumulation with repeated dosing, especially in renal impairment.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Renal excretion of propoxyphene and its metabolites accounts for approximately 70-90% of an administered dose, with less than 5% excreted as unchanged drug. The remainder is eliminated via bile and feces. Minor amounts are excreted in breast milk.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination